CN113304166A - 核苷类化合物在治疗冠状病毒感染性疾病中的用途 - Google Patents

核苷类化合物在治疗冠状病毒感染性疾病中的用途 Download PDF

Info

Publication number
CN113304166A
CN113304166A CN202010125799.2A CN202010125799A CN113304166A CN 113304166 A CN113304166 A CN 113304166A CN 202010125799 A CN202010125799 A CN 202010125799A CN 113304166 A CN113304166 A CN 113304166A
Authority
CN
China
Prior art keywords
acid
compound
formula
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010125799.2A
Other languages
English (en)
Other versions
CN113304166B (zh
Inventor
常俊标
杜锦发
蒋建东
李玉环
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Zhenshi Biotechnology Co ltd
Original Assignee
Henan Zhenshi Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202010125799.2A priority Critical patent/CN113304166B/zh
Application filed by Henan Zhenshi Biotechnology Co ltd filed Critical Henan Zhenshi Biotechnology Co ltd
Priority to CN202211442145.8A priority patent/CN116098917A/zh
Priority to JP2022551819A priority patent/JP2023516628A/ja
Priority to CA3167927A priority patent/CA3167927A1/en
Priority to KR1020227030688A priority patent/KR20220146496A/ko
Priority to MA57574A priority patent/MA57574A1/fr
Priority to MX2022010248A priority patent/MX2022010248A/es
Priority to EP21760199.6A priority patent/EP4112050A4/en
Priority to BR112022017209A priority patent/BR112022017209A2/pt
Priority to IL295840A priority patent/IL295840A/en
Priority to US17/905,142 priority patent/US20230277576A1/en
Priority to PCT/CN2021/077010 priority patent/WO2021169861A1/zh
Priority to AU2021228008A priority patent/AU2021228008A1/en
Publication of CN113304166A publication Critical patent/CN113304166A/zh
Priority to ZA2022/10636A priority patent/ZA202210636B/en
Application granted granted Critical
Publication of CN113304166B publication Critical patent/CN113304166B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

式(I)所示的化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，所述式(I)化合物用于治疗新冠状病毒肺炎病人，在病毒核酸试验转阴率、转阴疗程、治愈出院时间都显示明显优势。

Description

核苷类化合物在治疗冠状病毒感染性疾病中的用途
技术领域
本发明涉及核苷类化合物新的抗病毒用途。
背景技术
冠状病毒(Coronavirus,CoV)是一类有包膜的正向单链RNA病毒，在人类、其他哺乳动物和鸟类中广泛传播，并可导致呼吸道、肠道、肝脏和神经系统等疾病。目前已知有七种CoV可导致人类疾病，其中四种CoV-229E、-OC43、-NL63 和-HKU1在人群中流行，并通常引起普通感冒症状。而其他三种SARS-CoV、MERS-CoV和新冠状病毒(2019-nCoV，或称COVID-19)都具有发病快、传染性强和致死率高的严重危害性。因此，快速研发直接抗病毒药物，治疗新冠状病毒感染，十分迫切。
发明内容
化合物1作为抗艾滋病药物已经完成II期临床试验，安全性良好。
Figure RE-GDA0002510414330000011
发明人在新冠状病毒感染的MRC-5细胞内，测定了化合物1的体外抗病毒活性。结果表明，化合物1只有微弱的抑制新冠状病毒的活性(EC50为25μM)。
然而，发明人直接用式(1)化合物进行研究性临床试验，惊奇地发现，较对照性常规治疗，用式(1)化合物治疗新冠状病毒肺炎病人，在病毒核酸试验转阴率、转阴疗程、治愈出院时间都显示明显优势。发明人认为，化合物1没有显示明显抑制病毒作用，可能与其在体外中不能有效地磷酸酯化有关。
鉴于此，本文中一方面，提供式(I)所示的化合物、或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，另一方面，本文中提供一种预防或治疗冠状病毒感染性疾病的方法，包括向有此需要的患者给予治疗或预防有效量的式(I)化合物或其药学上可接受的盐，
其中式(I)结构式如下：
Figure RE-GDA0002510414330000021
式(I)中，
R1为OR1基团可以在体内代谢释放出羟基，或者形成O-磷酸基的任何基团； OR1优选为酯基，R1优选为H、R5-CO-、或
Figure RE-GDA0002510414330000022
其中Ar是苯基和取代苯基，萘基和取代萘基，所述取代基选自C1-6烷基、F、Cl、Br、I、CN、 N3、OH、NH2、OR5、NHR5；
R2选自:H、叠氮基、C1-C6烷基(例如甲基、乙基)、C1-C6烷氧基(例如甲氧基、乙氧基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)；
R3选自H、任选被取代的R-CO-、任选被取代的R-O(C＝O)-、和任选被取代的RNH-CO-，其中R选自C1-C6烷基(例如甲基、乙基、丙基、异丙基、丁基、异丁基、戊基、异戊基等)；其中，取代基选自C1-C6烷基、卤素(如F、Cl)、 CN、N3、和OR5。
R4选自H、OH、卤素(例如F)、C1-C6烷基(例如甲基，乙基)、C1-C6烷氧基(例如甲氧基，乙氧基)；
B选自：
Figure RE-GDA0002510414330000023
其中，X1选自-OH、-NH2、R5CONH-、R5COO-、R5O(C＝O)NH-；
X2选自-OH、-SH、-NH2、R5COO-、R5COS-、R5CONH2-、R5O(C＝O)NH-；
X3选自H、F、-OH和-NH2；
Y选自CH和N；
Z为H、-OH或F；
R5选自H、C1-C6烷基(例如甲基、乙基、丙基、异丙基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)、任选被C1-6烷基、C1-6烷氧基、CN、N3、OH、NH2、卤素 (例如F、Cl、Br、I)取代的苯基、任选被C1-6烷基、C1-6烷氧基、CN、N3、 OH、NH2、卤素(例如F、Cl、Br、I)取代的萘基。
优先如下化合物或其药学上可接受的盐：
Figure RE-GDA0002510414330000031
Figure RE-GDA0002510414330000041
式(I)化合物的药学上可接受的盐包括，但不限于，例如式(I)化合物与以下酸形成的盐：盐酸、氢溴酸、氨基磺酸、硫酸、磷酸、硝酸、甲酸、乙酸、丙酸、草酸、乙醇酸、丙二酸、苯甲酸、乳酸、葡糖酸、柠檬酸、酒石酸、琥珀酸、富马酸、马来酸、杏仁酸、苹果酸、甲磺酸、乙磺酸、羟乙基磺酸、苯磺酸、对甲苯磺酸、萘磺酸、萘二磺酸、樟脑磺酸、抗坏血酸棕榈酸、水杨酸、磺基水杨酸、2-羟基-3-萘甲酸、邻苯二甲酸、赖氨酸、精氨酸、谷氨酸、甘氨酸、丝氨酸、苏氨酸、丙氨酸、异亮氨酸、亮氨酸等。
式(I)化合物可通过商业渠道购买或者已知的方法制得。
本文中冠状病毒感染性疾病，是由冠状病毒科病毒感染所引发的疾病，包括感染人或其他动物所引起的疾病。特别是人冠状病毒感染人类所引发的疾病，包括但不限于CoV-229E、-OC43、-NL63、-HKU1、SARS-CoV、MERS-CoV和新冠状病毒(2019-nCoV，或称COVID-19)感染引起的疾病。
式(I)化合物的治疗和预防冠状病毒感染性疾病的有效量可由本领域技术人员根据本文提供的信息确定。例如，成年人用量可以为1-500mg/天，可选为1-50mg/天，可选为1-20mg/天；可选为1-10mg/天，可选为5mg/天。可以单次或分多次给药。
给药方式可以为口服或者胃肠外给药。可以是速释剂型，也可以是缓释剂型、控释剂型。具体剂型可是本领域的各种常规剂型。例如，口服制剂可以列举片剂、硬或软胶囊剂、水性或油性混悬剂、颗粒剂、乳剂、糖浆剂或酏剂等。注射剂可以列举注射液、粉针剂等。
具体实施方式
以下对本发明的具体实施方式进行详细说明。应当理解的是，此处所描述的具体实施方式仅用于示例性地对本发明进行说明，并不用于限制本发明。
试验例
临床试验验证化合物用于治疗新冠状病毒(COVID-19)肺炎的有效性和安全性。
选择20例通过核酸试剂测定确诊新冠状病毒感染的患者，分为阿兹夫定(化合物1)组和克力芝对照组，每组10例。阿兹夫定组治疗方案：每天服用5毫克(口服，5片，每片1毫克)；克力芝对照组治疗方案：克力芝(口服，2片/ 日，250mg/片)+阿比多尔片(口服200mg/次，3次/日)+干扰素(500万U，每日两次雾化吸入)。测定核酸变化，体温变化，观察各种症状。
结果如下表所示。
Figure RE-GDA0002510414330000051
Figure RE-GDA0002510414330000061
临床试验结果表明，10例新冠状病毒感染患者中，阿兹夫定组全部患者核酸检测转阴，其中7例第8天内出院。
上述临床试验结果表明，化合物1治疗新冠病毒肺炎在病人核酸转阴率、转阴疗程、治愈率和治愈疗程几个指标都显示显著临床治疗优势。
其中一例使用克力芝支持治疗20多天仍不能转阴的病人，采用化合物1治疗后3天转阴。治疗中，没有发现任何药物有关的毒副作用。

Claims (5)

1.式(I)所示的化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，
Figure FDA0002394361300000011
式(I)中，
R1为H、R5-CO-、或
Figure FDA0002394361300000012
其中Ar为苯基、取代苯基、萘基或取代萘基，其中取代基选自C1-6烷基、F、Cl、Br、I、CN、N3、OH、NH2、OR5、NHR5；
R2为:H、叠氮基、C1-C6烷基(例如甲基、乙基)、C1-C6烷氧基(如甲氧基、乙氧基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、或者卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)；
R3为H、任选被取代的R-CO-、任选被取代的R-O(C＝O)-、或任选被取代的RNH-CO-，其中R为C1-C6烷基(例如甲基、乙基、丙基、异丙基、丁基、异丁基、戊基、异戊基等)，其中，取代基选自C1-C6烷基、卤素(如F、Cl)、CN、N3、和OR5；
R4为H、OH、卤素(例如F)、C1-C6烷基(例如甲基，乙基)、或C1-C6烷氧基(例如甲氧基，乙氧基)；
B选自：
Figure FDA0002394361300000013
其中，X1为-OH、-NH2、R5CONH-、R5COO-或R5O(C＝O)NH-；
X2为OH、SH、NH2、R5COO-、R5COS-、R5CONH2-、或R5O(C＝O)NH-；
X3为H、F、OH或NH2；
Y为CH或N；
Z为H、OH或F；
R5选自H、C1-C6烷基(例如甲基、乙基、丙基、异丙基)、C2-C6炔基(例如乙炔基)、C2-C6烯基(例如乙烯基)、卤代C1-C6烷基(例如2-氯乙基、2-氟乙基、三氟乙基)、任选被C1-6烷基、C1-6烷氧基、CN、N3、OH、NH2、卤素(例如F、Cl、Br、I)取代的苯基、任选被C1-6烷基、C1-6烷氧基、CN、N3、OH、NH2、卤素(例如F、Cl、Br、I)取代的萘基。
2.根据权利要求1所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中式(I)所示化合物为下列化合物：
Figure FDA0002394361300000021
Figure FDA0002394361300000031
或者
Figure FDA0002394361300000032
3.根据权利要求1或2所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中式(I)化合物的药学上可接受的盐包括式(I)化合物与以下酸形成的盐：盐酸、氢溴酸、氨基磺酸、硫酸、磷酸、硝酸、甲酸、乙酸、丙酸、草酸、乙醇酸、丙二酸、苯甲酸、乳酸、葡糖酸、柠檬酸、酒石酸、琥珀酸、富马酸、马来酸、杏仁酸、苹果酸、甲磺酸、乙磺酸、羟乙基磺酸、苯磺酸、对甲苯磺酸、萘磺酸、萘二磺酸、樟脑磺酸、抗坏血酸棕榈酸、水杨酸、磺基水杨酸、2-羟基-3-萘甲酸、邻苯二甲酸、赖氨酸、精氨酸、谷氨酸、甘氨酸、丝氨酸、苏氨酸、丙氨酸、异亮氨酸或亮氨酸。
4.根据权利要求1-3任一项所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中所述冠状病毒感染性疾病是由冠状病毒科病毒感染所引发的疾病，包括感染人或其他动物所引起的疾病，尤其是人冠状病毒感染人类所引发的疾病，例如，CoV-229E、-OC43、-NL63、-HKU1、SARS-CoV、MERS-CoV或COVID-19感染引起的疾病。
5.根据权利要求1-3任一项所述的式(I)所示化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，其中所述药物剂型为速释剂型、缓释剂型、或控释剂型，例如片剂、硬、软胶囊剂、水性或油性混悬剂、颗粒剂、乳剂、糖浆剂、酏剂、注射液、或粉针剂。
CN202010125799.2A 2020-02-27 2020-02-27 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 Active CN113304166B (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN202211442145.8A CN116098917A (zh) 2020-02-27 2020-02-27 核苷类化合物在治疗冠状病毒感染性疾病中的用途
CN202010125799.2A CN113304166B (zh) 2020-02-27 2020-02-27 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
PCT/CN2021/077010 WO2021169861A1 (zh) 2020-02-27 2021-02-20 核苷类化合物在治疗冠状病毒感染性疾病中的用途
KR1020227030688A KR20220146496A (ko) 2020-02-27 2021-02-20 뉴클레오티드계 화합물의 코로나 바이러스 감염증의 치료에의 사용
MA57574A MA57574A1 (fr) 2020-02-27 2021-02-20 Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus
MX2022010248A MX2022010248A (es) 2020-02-27 2021-02-20 Uso de compuesto de nucleosidos en el tratamiento de enfermedades infecciosas por coronavirus.
EP21760199.6A EP4112050A4 (en) 2020-02-27 2021-02-20 USE OF A NUCLEOSIDE COMPOUND IN THE TREATMENT OF CORONAVIRUS INFECTIOUS DISEASES
BR112022017209A BR112022017209A2 (pt) 2020-02-27 2021-02-20 Uso de composto nucleosídeo no tratamento de doenças infecciosas por coronavírus
JP2022551819A JP2023516628A (ja) 2020-02-27 2021-02-20 ヌクレオチド系化合物のコロナウイルス感染症の治療での使用
US17/905,142 US20230277576A1 (en) 2020-02-27 2021-02-20 A method for preventing or treating a cornavirus infectious disease
CA3167927A CA3167927A1 (en) 2020-02-27 2021-02-20 Use of nucleoside compound in treatment of coronavirus infectious diseases
AU2021228008A AU2021228008A1 (en) 2020-02-27 2021-02-20 Use of nucleoside compound in treatment of coronavirus infectious diseases
IL295840A IL295840A (en) 2020-02-27 2021-02-20 Use of a nucleoside compound in the treatment of infectious coronavirus diseases
ZA2022/10636A ZA202210636B (en) 2020-02-27 2022-09-26 Use of nucleoside compound in treatment of coronavirus infectious diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010125799.2A CN113304166B (zh) 2020-02-27 2020-02-27 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211442145.8A Division CN116098917A (zh) 2020-02-27 2020-02-27 核苷类化合物在治疗冠状病毒感染性疾病中的用途

Publications (2)

Publication Number Publication Date
CN113304166A true CN113304166A (zh) 2021-08-27
CN113304166B CN113304166B (zh) 2022-10-14

Family

ID=77370412

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211442145.8A Pending CN116098917A (zh) 2020-02-27 2020-02-27 核苷类化合物在治疗冠状病毒感染性疾病中的用途
CN202010125799.2A Active CN113304166B (zh) 2020-02-27 2020-02-27 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211442145.8A Pending CN116098917A (zh) 2020-02-27 2020-02-27 核苷类化合物在治疗冠状病毒感染性疾病中的用途

Country Status (13)

Country Link
US (1) US20230277576A1 (zh)
EP (1) EP4112050A4 (zh)
JP (1) JP2023516628A (zh)
KR (1) KR20220146496A (zh)
CN (2) CN116098917A (zh)
AU (1) AU2021228008A1 (zh)
BR (1) BR112022017209A2 (zh)
CA (1) CA3167927A1 (zh)
IL (1) IL295840A (zh)
MA (1) MA57574A1 (zh)
MX (1) MX2022010248A (zh)
WO (1) WO2021169861A1 (zh)
ZA (1) ZA202210636B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114288313A (zh) * 2022-02-18 2022-04-08 常晓宇 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途
CN114504578A (zh) * 2022-03-03 2022-05-17 苏州旺山旺水生物医药有限公司 治疗、预防由病毒感染引起的相关疾病的药物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1472336A (zh) * 2003-06-04 2004-02-04 中国科学院上海药物研究所 Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物
CN1784239A (zh) * 2003-05-06 2006-06-07 西托维亚公司 冠状病毒和sars－cov的蛋白酶抑制剂及其应用
CN109890808A (zh) * 2016-08-19 2019-06-14 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
US20190185509A1 (en) * 2017-12-20 2019-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3089590A1 (en) * 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
US20200030327A1 (en) * 2018-07-30 2020-01-30 Gilead Sciences, Inc. Anti-hiv compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1425022A4 (en) * 2001-08-24 2009-04-29 Koronis Pharmaceuticals Inc MUTAGENIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF VIRAL DISEASE
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784239A (zh) * 2003-05-06 2006-06-07 西托维亚公司 冠状病毒和sars－cov的蛋白酶抑制剂及其应用
CN1472336A (zh) * 2003-06-04 2004-02-04 中国科学院上海药物研究所 Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物
CN109890808A (zh) * 2016-08-19 2019-06-14 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
US20190185509A1 (en) * 2017-12-20 2019-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3089590A1 (en) * 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
US20200030327A1 (en) * 2018-07-30 2020-01-30 Gilead Sciences, Inc. Anti-hiv compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘白璐: "《STN检索报告》", 29 June 2022 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114288313A (zh) * 2022-02-18 2022-04-08 常晓宇 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途
CN114504578A (zh) * 2022-03-03 2022-05-17 苏州旺山旺水生物医药有限公司 治疗、预防由病毒感染引起的相关疾病的药物及其用途

Also Published As

Publication number Publication date
KR20220146496A (ko) 2022-11-01
CN116098917A (zh) 2023-05-12
MA57574A1 (fr) 2023-11-30
CA3167927A1 (en) 2021-09-02
WO2021169861A1 (zh) 2021-09-02
AU2021228008A1 (en) 2022-09-22
BR112022017209A2 (pt) 2022-10-11
CN113304166B (zh) 2022-10-14
IL295840A (en) 2022-10-01
MX2022010248A (es) 2022-10-10
JP2023516628A (ja) 2023-04-20
ZA202210636B (en) 2024-01-31
US20230277576A1 (en) 2023-09-07
EP4112050A1 (en) 2023-01-04
EP4112050A4 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
JP5209180B2 (ja) トリインフルエンザ感染の治療
CN113304166B (zh) 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
KR20100103845A (ko) 바이러스 감염 치료용 아세틸살리실산 염
EP3317290A1 (en) Compositions and methods for the treatment of viral infection
WO2013044871A1 (zh) 氯喹或氯丙嗪或其衍生物或它们的混合物在制备用于治疗和/或预防肺感染和损伤的药物中的用途
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
CN112121044B (zh) 氨来占诺用于制备抗肝炎病毒药物的用途
EP3934653B1 (en) Azelastine as antiviral treatment
CA3190278A1 (en) Antiviral use of liraglutide and gefitinib
JP2010528053A (ja) インフルエンザ感染症を治療するための物質および方法
WO2022145405A1 (ja) Ｄｐ１アンタゴニストおよびキャップ依存性エンドヌクレアーゼ阻害剤からなるウイルス性気道感染症治療用医薬
AU2010317727A1 (en) Treatment of microbial infections
WO2022145407A1 (ja) Ｄｐ１アンタゴニストおよびノイラミニダーゼ阻害剤からなるウイルス性気道感染症治療用医薬
CN112691094B (zh) 防治病毒的新型化合物及其应用
WO2024093813A1 (zh) 核苷类化合物的制药用途
JP2004292399A (ja) 抗ウイルス剤
WO2022144779A1 (en) Sulfonamide derivatives, compositions comprising same and uses thereof against rna viruses
WO2021205153A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
WO2021195185A1 (en) Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof
JP2003155230A (ja) 抗インフルエンザ薬
CN112641918A (zh) 姜粉在制备治疗病毒性感冒的药物中的应用
Asmar et al. Antiviral therapy: Respiratory infections, chornic hepatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant